Hypertension by Oparil, Suzanne et al.
 
 
 
 
 
Oparil, S. et al. (2018) Hypertension. Nature Reviews Disease Primers, 4, 
18014. (doi:10.1038/nrdp.2018.14) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/157308/  
                    
 
 
 
 
 
 
Deposited on: 19 March 2018 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 Page 2 of 53 
 
Hypertension 1 
Suzanne Oparil1, Maria C. Acelajado2, George Bakris3, Dan Berlowitz4, Renata Cífková5, Anna 2 
Dominiczak6, Guido Grassi7, Jens Jordan8, Neil Poulter9, Anthony Rodgers10 and Paul K Whelton11 3 
1  Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department 4 
of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, 5 
Alabama, United States of America (U.S.A.), 35294-0007 6 
2  Athens-Limestone Hospital, Athens, Alabama, United States of America (U.S.A.) 7 
3 University of Chicago Medicine, Chicago, Illinois, United States of America (U.S.A.) 8 
4 Center for Healthcare Organization and Implementation Research, Bedford Veteran Affairs 9 
Medical Center, Bedford, Massachusetts, and Schools of Medicine and Public Health, Boston 10 
University, Boston, Massachusetts, United States of America (U.S.A.) 11 
5 Center for Cardiovascular Prevention,  Charles University in Prague, First Faculty of Medicine 12 
and Thomayer Hospital, Prague, Czech Republic 13 
6 Institute of Cardiovascular and Medical Science, College of Medical, Veterinary and Life 14 
Sciences, University of Glasgow, United Kingdom (U.K.) 15 
7 Clinica Medica, University of Milano-Bicocca, Milan, Italy, and IRCCS Multimedica, Sesto San 16 
Giovanni, Milan, Italy 17 
8 Institute of Aerospace Medicine, German Aerospace Center (DLR), University of Cologne, 18 
Cologne, Germany 19 
9 Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, United 20 
Kingdom (U.K.) 21 
10 The George Institute for Global Health, Sydney, New South Wales, Australia 22 
11 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 23 
New Orleans, Louisiana, United States of America (U.S.A.) 24 
 25 
Correspondence to: S.O. soparil@uabmc.edu  26 
  27 
 Page 3 of 53 
 
Competing interests 28 
G.B. served as Consultant for Janssen, Bayer, AbbVie, Vascular Dynamics, Relypsa, Merck, 29 
Medtronic; served/serves as Principal Investigator for FIDELIO trial (Bayer), Steering Committee 30 
member (CREDENCE)-Janssen, SONAR-AbbVie, and CALM-2-Vascular Dynamics. J.J. served as 31 
consultant for Novartis, Novo-Nordisc, Boehringer-Ingelheim, Sanofi, Orexigen, Riemser, Theravance, 32 
Vivus; and is cofounder of Eternygen GmbH. S.O. (in the previous 24 months) has received research 33 
grant support or reimbursement for travel to meetings or other, non-financial support from Actelion 34 
Clinical Research/George Clinical; AstraZeneca AB; Bayer; Lundbeck; Novartis; Novo Nordisk; Rox 35 
Medical; has consulted for Actelion/George Clinical, Lundbeck, Novo Nordisk and ROX Medical; served 36 
as Director/Principal Investigator, SPRINT University of Alabama at Birmingham (UAB) Clinical Center 37 
Network (CCN); and sub-investigator UAB CCN clinical site; for which Takeda and Arbor 38 
Pharmaceuticals donated 5% of medication used. N.R.P. served as advisory board member (ad hoc) 39 
for Pfizer, Takeda, MSD, Servier, and Medtronic (companies producing blood pressure lowering 40 
agents/devices); received speaker honoraria from Servier, AstraZeneca, Napi Labs, and Menarini; and 41 
received research funding from Servier, Pfizer and Menarini. George Health Enterprises, the social 42 
enterprise arm of The George Institute for Global Health, has applied for a patent in the area of low-43 
dose combinations on which A.R. is listed as an inventor; and has received investment to develop 44 
fixed-dose combinations containing aspirin, statin and BP lowering drugs. AR is an investigator on 45 
grants for several trials of blood pressure lowering interventions. M.C.A., R.C., A.F.D., G.G. and P.K.W. 46 
declare no competing interests. Editor’s note: D.R.B. has chosen not to declare any competing 47 
interests, but may do so later.  48 
Author contributions  49 
Introduction (M.C.A., and S.O.); Epidemiology (A.R.); Mechanisms/pathophysiology (G.B. and G.G.); 50 
Diagnosis, screening and prevention (A.F.D. and P.K.W.); Management (J.J. and R.C.); Quality of life 51 
(D.R.B.); Outlook (N.R.P.); overview of Primer (S.O.). 52 
  53 
 Page 4 of 53 
 
ABSTRACT 54 
Systemic hypertension is the most important modifiable risk factor for all-cause morbidity and 55 
mortality worldwide. Less than half of hypertensive persons are aware of their condition, and many 56 
others are aware but not treated, or inadequately treated. Successful treatment of hypertension 57 
reduces the global burden of disease and mortality. The etiology of hypertension involves the complex 58 
interplay of pathophysiologic and environmental factors that act on a genetic background. Evaluation of 59 
patients with hypertension includes accurate standardized blood pressure (BP) measurement, 60 
assessing patients’ predicted risk of atherosclerotic cardiovascular disease (ASCVD), evidence of 61 
target organ damage, detection of secondary causes of hypertension, and presence of comorbidities, 62 
including CVD and kidney disease. New paradigms for hypertension treatment consider predicted 63 
ASCVD risk rather than BP values alone, since persons at high-risk for CVD are most likely to benefit 64 
from treatment. Nonpharmacological interventions including dietary modifications and increased 65 
physical activity are effective in lowering BP and preventing hypertension and its CVD sequelae. 66 
Pharmacological therapy is very effective in lowering BP and preventing CVD outcomes in most 67 
persons with hypertension. 68 
[H1] INTRODUCTION  69 
Systemic arterial hypertension is persistently high BP in the systemic arteries. Several 70 
aetiologies can underlie hypertension. A positive family history is a frequent occurrence in hypertensive 71 
patients, with the heritability estimated to vary between 35% and 50% in the majority of studies1,2. 72 
Several rare, monogenic forms of hypertension have been described, e.g., the Liddle’s syndrome, 73 
glucocorticoid-remediable aldosteronism and PDE 3A mutations, where a single gene mutation fully 74 
explains the pathogenesis of hypertension and dictates the best treatment modality3,4,5. If hypertension 75 
is caused by another condition (such as aldosteronism, pheochromocytoma or renal artery stenosis), it 76 
is referred to as secondary hypertension.  77 
 78 
The great majority of patients suffer from a highly heterogeneous “essential” or primary 79 
hypertension with a multifactorial gene-environment etiology. Genome-wide association studies 80 
(GWAS) have identified approximately 120 loci which are associated with BP regulation and together 81 
explain 3.5% of the trait variance6,7,8. These findings are becoming increasingly important as we search 82 
for new pathways and new biomarkers to develop more modern “omics”-driven diagnostic and 83 
therapeutic modalities for hypertension in the era of precision medicine9. 84 
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Hypertension is the most common preventable risk factor for heart failure, stroke, myocardial 85 
infarction, atrial fibrillation, chronic kidney disease (CKD), and cognitive impairment, and is the leading 86 
single contributor to all-cause death and disability worldwide. The relationship between BP and the risk 87 
of CVD is graded and continuous, with no evidence of a threshold, down to a BP of 115/75 mmHg, well 88 
within what is considered to be the normotensive range. The probability of dying from ischemic heart 89 
disease or stroke is doubled for every 20 mmHg rise in systolic BP (that is, the pressure that the blood 90 
exerts on the arterial walls when the heart contracts) or 10 mmHg elevation in diastolic BP (the 91 
pressure when the heart relaxes) in middle aged and elderly persons10, and a systolic BP reduction of 5 92 
mmHg in the population can decrease stroke mortality by 14% and CVD mortality by 9%. Successful 93 
prevention and treatment of hypertension are key in reducing disease burden and promoting longevity 94 
in the world’s population. 95 
BP is regulated by a complex interplay of various elements of the cardiovascular, endocrine, 96 
renal and neural systems, and compensatory mechanisms arising from elevated BP result in target 97 
organ damage, for example, left ventricular hypertrophy and CKD and CVD outcomes, such as stroke 98 
and heart failure. It is important to consider a person’s predicted ASCVD risk, more than the level of BP 99 
alone, in treating hypertension, since persons with high CVD risk derive the greatest benefit from BP 100 
lowering treatment. This Primer will discuss the epidemiology and pathophysiology of hypertension, 101 
strategies for preventing and slowing the progression of BP elevation, best strategies (including optimal 102 
BP targets) for lowering BP and preventing CVD outcomes in patients with established hypertension, 103 
effects of antihypertensive treatment on quality of life, and explore knowledge gaps, future trends and 104 
outlook for hypertension research and treatment over the next decade. 105 
[H1] EPIDEMIOLOGY  106 
In pre-industrial societies, BP levels had narrow distributions with mean values that changed 107 
little with age and averaged around 115/75 mmHg11, likely representing normal (or ideal) BP for our 108 
species. In most contemporary societies, systolic BP levels rise steadily and continuously with age in 109 
both men and women. This ubiquitous finding arises because age is a proxy for likelihood and duration 110 
of exposure to the numerous environmental factors that increase BP gradually over time, such as 111 
excessive sodium consumption, overweight and obesity, alcohol intake and physical inactivity. Other 112 
factors, such as genetic predisposition or adverse intrauterine environment, have small but definite 113 
associations with high levels of adult BP12. Even modest rises in mean population BP lead to large 114 
increases in the absolute number of people with hypertension13.  115 
As economic development progresses, high BP initially affects higher socioeconomic groups 116 
and later disproportionately affects those with lower socioeconomic status. This phenomenon is seen 117 
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both within and between countries – for example, North America and Sub-Saharan Africa have had 118 
opposite trends of BP levels in recent decades14 Further, the speed of change in recent decades has 119 
been much more rapid than in previous epidemiological transitions. Over the last several decades age-120 
standardized mean adult BP levels have increased steadily in South America, sub-Saharan Africa, 121 
South Asia and South East Asia, while they have fallen in other regions, most notably Western Europe 122 
and North America14. Adult age-standardized BP levels are now highest in Russia, Eastern Europe, 123 
Central Asia and much of sub-Saharan Africa, with mean adult systolic BP levels over 130mmHg in 124 
these areas. BP levels are now lowest in North America, following a gradual decline in recent 125 
decades14. Globally, 3.5 billion adults now have non-optimal systolic BP levels (i.e. above 110 to 115 126 
mmHg) and 874 million adults have systolic BP ≥140 mmHg. Thus, approximately one in four adults 127 
has hypertension. Between 1990 and 2015 there was a 43% increase in the total global number of 128 
healthy life years lost to non-optimal BP, driven by population increase, population aging, and a 10% 129 
increase in the age-standardized rate of high BP 14. 130 
Multiple prospective observational studies have shown a positive association between BP levels 131 
and coronary heart disease, ischemic stroke, hemorrhagic stroke and most major subtypes of 132 
CVD10,15.These associations have generally been direct and continuous from the lowest levels of BP, 133 
although there are variations in the strength of the associations and the slopes of the lines relating 134 
systolic, diastolic and other indices of BP with CVD. The Global Burden of Disease project has shown 135 
that non-optimal BP continues to be the biggest single risk factor contributing to the global burden of 136 
disease and to global all-cause mortality, leading to 9·4 million deaths and 212 million lost healthy life 137 
years (8.5% of the global total) each year16. (Figure 1) 138 
 139 
[H2] Hypertension is a risk factor for CVD  140 
Observational studies have repeatedly demonstrated a strong, continuous relationship between 141 
BP and CVD, with no evidence of a threshold for risk throughout the usual range of BP in clinical 142 
practice10,15,17.The relationship applies to both systolic BP and diastolic BP, but is somewhat more 143 
robust for systolic BP in adults17. It is noted in both sexes, is seen at all ages throughout adulthood, and 144 
is apparent for all major manifestations of CVD, including stroke, coronary artery disease, heart failure, 145 
peripheral vascular disease, and end stage renal disease10,15,17,18. The relationship is independent of 146 
other CVD risk factors, and level of BP has proven to be a major component of all CVD risk prediction 147 
models. Approximately two-thirds of all adults who have hypertension (systolic BP ≥140 mmHg or 148 
diastolic BP ≥90 mmHg or treatment with BP lowering medication) at 30 years of age are likely to 149 
experience a CVD event during their lifetime, which is about 40 % higher than the corresponding risk 150 
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for their counterparts with a lower level of BP15. In addition, CVD events in those with hypertension are 151 
likely to manifest about five years earlier than in those with a lower level of BP15. 152 
At ages 40-69 years, a 20 mmHg higher level of systolic BP or a 10 mmHg higher level of diastolic BP 153 
at any point in the distribution is associated with more than a doubling of the risk for stroke mortality10. 154 
At older ages, the corresponding relative risk is slightly less but the absolute risk is far greater than 155 
earlier in life10. Figure 2 displays the relationship between systolic BP and a specific CVD outcome, 156 
coronary heart disease (CHD) mortality, during an average of 11.1 years of follow-up in 347,978 157 
adults17. Those with the highest BPs were at greatest risk for CVD mortality (Figure 2A). Figure 2B 158 
demonstrates that only a minority of the sample was exposed to the high risk associated with 159 
hypertension (≥140 mmHg for systolic BP). However, a much larger number of them were exposed to 160 
the more modest but still important increases in CVD risk within the non-hypertensive range of BP. 161 
Combining information about incidence (Figure 2A) and prevalence (Figure 2B) allows for estimation of 162 
the excess risk that results from each category of BP. This suggests that about 25% of the overall 163 
burden of BP-related CHD mortality occurred in approximately 5% of adults who had a systolic BP ≥160 164 
mmHg, whereas almost 45% occurred in the approximately 20% who had a systolic BP ≥ 140 mmHg 165 
but <160 mmHg, and >30% occurred in the approximately 75% of adults with a systolic BP <140 166 
mmHg. About two-thirds of the latter could be attributed to the approximately 20% of adults who had a 167 
systolic BP in the high-normal range (systolic BP 130-139 mmHg)19. 168 
 169 
[H1] MECHANISMS/PATHOPHYSIOLOGY 170 
[H2] BP regulation 171 
BP is determined by several factors, including blood volume and cardiac output (the amount of 172 
blood pumped by the heart per minute). Moreover, maintenance of BP involves an integrated 173 
neurohumoral system that includes the sympathetic nervous system (SNS), renin-angiotensin-174 
aldosterone system (RAAS), release of nitric oxide (NO) from the endothelium and central mechanisms 175 
from relay centers the brain. Malfunction or disruption in any of these systems will result in either 176 
increases in mean BP or increased BP variability or both. Sodium (Na+) is a crucial regulator or blood 177 
volume: high serum Na+ concentration promotes fluid (water) retention, thereby increasing blood 178 
volume and BP. Natriuresis (the excretion of Na+ in the urine) is controlled by the kidneys. Salt 179 
sensitivity is defined as a marked elevation in BP following a Na+ load of 5 or more grams and is 180 
characterized by an elevation of systolic BP of at least 10 mmHg within a few hours of ingestion.  181 
The pathophysiological mechanisms responsible for systemic hypertension are complex. 182 
Functional alterations of several factors involved in BP control have been shown to favor BP elevation 183 
directly or indirectly and thus, to act as promoters of hypertension. These factors, which include the 184 
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RAAS, SNS, NO, inflammation, and in some circumstances, vasopressin and endothelin, appear to act 185 
on a genetic background. Primary hypertension involves multiple types of genes. Some allelic variants 186 
of several genes are associated with an increased risk of developing primary hypertension and are 187 
linked in almost all cases to a positive family history. This predisposition to develop the disorder, along 188 
with a host of environmental factors, such as high Na+ intake, poor sleep quality or sleep apnoea, 189 
excess alcohol intake, and high mental stress, contribute to the development of hypertension. Aging is 190 
major determinant of hypertension development due to slowly developing changes in vascular collagen 191 
that support the arterial structure, increases in atherosclerosis and other related factors that lead to 192 
vascular stiffening with age. Immunologic factors can also play a major part, especially on the 193 
background of infectious or rheumatologic diseases such as rheumatoid arthritis. The mosaic theory of 194 
hypertension describes its multifaceted pathophysiology20 . An updated version of this theory is 195 
provided in Figure 3, which illustrates the major mechanisms participating in the pathogenesis of 196 
chronic hypertension in humans21. 197 
 198 
[H2] Renin-Angiotensin-Aldosterone System (RAAS) 199 
 200 
The RAAS has wide-ranging effects on BP regulation, mediating Na+ retention, pressure natriuresis 201 
(i.e., the mechanism whereby increases in renal perfusion pressure lead to decreased Na+ reabsorption 202 
and increased Na+ excretion), salt sensitivity, vasoconstriction, endothelial dysfunction, and vascular 203 
injury, and plays an important role in the pathogenesis of hypertension. Renin and pro-renin are 204 
synthesized and stored in the juxtaglomerular cells of the kidney and are released in response to 205 
decreased renal afferent perfusion pressure, reduced Na+ delivery to the macula densa, activation of 206 
renal sympathetic nerves (via β1 adrenergic receptor stimulation), and a variety of vasodilators, 207 
including prostaglandin E2 (Figure 3). The main function of renin is to cleave angiotensinogen to form 208 
angiotensin I. Angiotensin-converting enzyme (ACE) cleaves angiotensin I to form angiotensin II, which 209 
is at the center of the pathogenetic role of the RAAS in hypertension. Angiotensin II activates the AT1 210 
receptor, triggering smooth muscle cell contraction, systemic vasoconstriction, increased renovascular 211 
resistance and decreased renal medullary blood flow, a mediator of salt sensitivity. Salt sensitivity is 212 
defined clinically by BP increases in response to increased Na+ intake (Figure 4).  213 
 Angiotensin II enhances Na+ reabsorption in the proximal tubule by increasing the activity of the 214 
sodium-hydrogen exchanger (NHE3), sodium-bicarbonate exchanger, and sodium-potassium ATPase, 215 
and by inducing aldosterone synthesis and release from the adrenal glomerulosa. Angiotensin II is also 216 
associated with endothelial dysfunction and has pro-fibrotic and pro-inflammatory effects, largely 217 
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mediated by increased oxidative stress, resulting in renal, cardiac, and vascular injury. Angiotensin II is 218 
tightly linked to target organ damage in hypertension via these mechanisms22. Stimulation of the AT2 219 
receptor has opposite effects, resulting in vasodilation, natriuresis and anti-proliferative actions. Cross-220 
transplantation studies using wild-type mice and mice lacking the AT1 receptor have shown that both 221 
systemic and renal actions of angiotensin II are relevant to physiologic BP regulation, but that the 222 
detrimental effects of angiotensin II in hypertension are mediated mainly via the kidney23,24. 223 
  Angiotensin-converting enzyme 2 (ACE2) has recently emerged as a key player in the 224 
pathophysiology of hypertension and CV and renal disease due to its role in metabolizing angiotensin II 225 
into angiotensin-(1-7).i Ang-(1-7) induces systemic and regional vasodilation, diuresis and natriuresis, 226 
and exerts antiproliferative and antigrowth effects on vascular smooth muscle cells, cardiac myocytes 227 
and fibroblasts as well as glomerular and proximal tubular cells. Ang-(1-7) also has cardiorenal 228 
protective effects that are mediated by the mas receptor through signaling pathways that include 229 
mitogen-activated protein kinases (MAPK), PI3K-AKT, NADPH oxidase, TGF-β1, the EGF receptor, 230 
and NF-κB activity. ACE inhibitors and AT1 receptor antagonists have been shown to increase Ang-(1-231 
7) levels in plasma and urine of normotensive animals and enhance renal ACE2 activity. (Varagic et al 232 
ref). Studies in rodents and humans with non-diabetic kidney disease suggest that upregulation of 233 
ACE2 may delay progression of kidney disease.iii 234 
Aldosterone plays a critical role in hypertension through stimulation of renal Na+ reabsorption 235 
mediated by non-genomic effects through the mineralocorticoid receptor, leading to increased 236 
expression of ENaC25. Aldosterone also has many non-epithelial effects that contribute to endothelial 237 
dysfunction, vasoconstriction and hypertension25,26. These include vascular smooth muscle cell 238 
proliferation, vascular extracellular matrix deposition, vascular remodeling, fibrosis, and increased 239 
oxidative stress. 240 
 [H2] Natriuretic Peptides 241 
Natriuretic peptides (atrial [ANP], brain [BNP] and urodilatin) play an important part in salt 242 
sensitivity and hypertension. They have important natriuretic and vasodilator properties that allow 243 
maintenance of Na+ balance and BP during Na+ loading. Upon administration of a Na+ load, atrial and 244 
ventricular stretch leads to release of ANP and BNP, respectively, resulting in BP lowering due to 245 
systemic vasodilation and decreased plasma volume, the latter caused by fluid shifts from the 246 
intravascular to the interstitial compartment27. Natriuretic peptides increase glomerular filtration rate via 247 
an increase in efferent arteriolar tone in volume-expanded states and inhibit renal Na+ reabsorption 248 
through both direct and indirect effects. Direct effects include decreased activity of the Na+-ATPase 249 
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and the sodium-glucose co-transporter in the proximal tubule and inhibition of the epithelial sodium 250 
channel in the distal nephron. Indirect effects include inhibition of renin and aldosterone release. In 251 
addition to promoting hypertension, natriuretic peptide deficiency predisposes to insulin resistance and 252 
type 2 diabetes mellitus. Obesity is associated with relative natriuretic peptide deficiency, likely through 253 
upregulation of the natriuretic peptide scavenger receptor NPR-C in adipose tissue. The metabolic 254 
effects of natriuretic peptides and their therapeutic potential for the metabolic syndrome have been 255 
reviewed recently28. 256 
A large GWAS of 2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) in 257 
69395 individuals of European ancestry from 29 studies demonstrated that most SNPs related to BP 258 
regulation and CVD risk involved natriuretic peptides29. Genes that encode precursors for ANP and 259 
BNP were noted and correlated with previous work that identified SNPs at this locus. Two other loci 260 
identified in this study contain genes involved in natriuretic peptide and related NO signaling pathways, 261 
both of which regulate cyclic guanosine monophosphate. A more recent study analyzed 128,272 SNPs 262 
from targeted and genome-wide arrays in 201,529 individuals of European ancestry, and genotypes 263 
from an additional 140,886 individuals were used for validation7. The study identified 66 BP–associated 264 
loci, which were enriched for cis-regulatory elements in vascular endothelial cells, consistent with a role 265 
in BP control through modulation of vascular tone. This information prompted development of a genetic 266 
risk score to predict target organ damage7.  267 
Gene deletion studies in rodent models have evaluated cardiac ANP and BNP as paracrine 268 
regulators of vascular regeneration. Mice with systemic deletion of the endothelial guanylyl cyclase-A 269 
(GC-A) receptor gene exhibit diminished vascular regeneration and angiogenesis in response to critical 270 
hind limb ischemia, and cardiac tissue in these animals shows fibrosis, diastolic dysfunction and 271 
diminished angiogenesis. In contrast, smooth muscle cell-restricted GC-A ablation did not affect 272 
ischemic neovascularization, suggesting that cardiac BNP regulates endothelial regeneration via GC-273 
A.[i] 274 
A case control study in Malaysia found a significant association between I/D polymorphisms of the 275 
ANP gene in hypertensive patients without diabetes, yet no association between G191A 276 
polymorphisms of ANP in hypertensive individuals was found.[ii] Together, these data suggest that ANP 277 
gene polymorphisms may affect hypertension, but the data are not definitive. 278 
Corin is a serine protease that is largely expressed in the heart and converts pro-ANP and pro-279 
BNP to their active forms. Corin deficiency has been associated with Na+ overload, heart failure and 280 
salt-sensitive hypertension30. Further, clinical studies have observed an association between certain 281 
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corin gene polymorphisms and risk of pre-eclampsia and hypertension, particularly among African-282 
American but not Chinese populations31.  283 
 284 
[H2] The Endothelium  285 
The endothelium is a major regulator of vascular tone and major contributor to salt sensitivity through 286 
NO. Endothelial cells produce a host of vasoactive substances, of which NO is the most important in 287 
BP regulation. NO is continuously released by endothelial cells in response to flow-induced shear 288 
stress, leading to vascular smooth muscle relaxation through activation of guanylate cyclase and 289 
generation of intracellular cyclic guanosine monophosphate32. Interruption of NO production via 290 
inhibition of constitutively expressed endothelial NO synthase (eNOS) causes BP elevation and 291 
development of hypertension in animals and humans. Studies using brachial artery flow-mediated 292 
vasodilation and measurement of urinary excretion of NO metabolites to evaluate NO activity in 293 
humans have demonstrated decreased whole-body production of NO in patients with hypertension 294 
compared with normotensive controls33,34 . 295 
Endothelial dysfunction plays a seminal role in the pathogenesis of hypertension. Normotensive 296 
offspring of hypertensive parents have impaired endothelium-dependent vasodilation, suggesting a 297 
genetic component in the development of endothelial dysfunction34. Endothelial dysfunction in the 298 
setting of chronic hypertension is related to a combination of direct pressure-induced injury and 299 
increased oxidative stress. Several enzyme systems, including NADPH oxidase, xanthine oxidase and 300 
cyclooxygenase, as well as decreased activity of superoxide dismutase generate reactive oxygen 301 
species.34,35. Excess superoxide anions bind to NO, decreasing NO bioavailability and generating the 302 
pro-inflammatory oxidant, peroxynitrite. Decreased NO bioavailability is the central factor that links 303 
oxidative stress to endothelial dysfunction and hypertension36. Recent studies documented that salt-304 
sensitive subjects may be very sensitive to the hemodynamic stress of increased effective blood 305 
volume, leading to overproduction of TGF-beta, oxidative stress, and limiting bioavailable NO37. 306 
Angiotensin II, along with other factors, including cyclic vascular stretch, endothelin-1 (ET-1), uric acid, 307 
systemic inflammation, norepinephrine, free fatty acids, and tobacco smoking, enhances NADPH 308 
oxidase activity and plays a central role in the generation of oxidative stress in hypertension38. 309 
 Endothelial cells also secrete a variety of other vasoregulatory substances, including 310 
vasodilators such as prostacyclin and endothelium-derived hyperpolarizing factors, and 311 
vasoconstrictors such as locally generated angiotensin II and the prostanoids thromboxane A2 and 312 
prostaglandin A2. Other vasodilating substances such as calcitonin gene related peptide, 313 
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adrenomedullin and substance P act primarily through increases in NO release from endothelial cells. 314 
The glucose-regulating gut hormone glucagon-like peptide-1 (GLP-1) also has vasodilating properties41. 315 
The balance between these factors, along with NO and ET-1, determines the final impact of the 316 
endothelium on vascular tone38,39,40,41.  317 
ET-1 is a potent vasoconstrictor that activates ET-A receptors in vascular smooth muscle39. Circulating 318 
ET-1 levels are not consistently increased in hypertension, but there is a trend toward increased 319 
sensitivity to the vasoconstrictor effects of ET-1 in hypertensive subjects40. ET-1 is a mediator of BP 320 
elevation, and ET-A and ET-B receptor antagonists attenuate or abolish hypertension in a variety of 321 
experimental models  (angiotensin II-mediated hypertension, DOCA-salt hypertension, and Dahl salt 322 
sensitive rats) and are effective in lowering BP in humans39,40. 323 
 324 
[H2] Sympathetic Nervous System (SNS) 325 
Baroreceptors, the rheostats of the circulatory system, are housed in various locations in the arterial 326 
tree, a key place being the bifurcation of the common carotid artery. When the artery is stretched by 327 
elevated BP, nerve bundles projecting from the carotid sinus baroreceptor send messages to the brain 328 
to reduce sympathetic outflow and, thereby, BP. The SNS is generally more activated in hypertensive 329 
persons compared with normotensive individuals.42 SNS activity is also greater in obese persons, in 330 
men than in women, in younger than in older persons, and in those with advanced kidney disease.46 47 331 
Many hypertensive patients are in a state of autonomic imbalance with increased sympathetic and 332 
decreased parasympathetic activity43,44. SNS hyperactivity is relevant to both the generation and 333 
maintenance of hypertension. Studies in humans have identified markers of sympathetic overactivity in 334 
normotensive individuals with a family history of hypertension45. Among hypertensive patients, 335 
increasing severity of hypertension is associated with increasing levels of sympathetic activity 336 
measured by microneurography48,49. Plasma catecholamine levels, microneurographic recordings and 337 
systemic catecholamine spillover studies have given evidence of increased sympathetic activity in 338 
hypertensive patients who are obese, in those with the metabolic syndrome, and in those whose 339 
hypertension is complicated by heart failure or kidney disease49.  340 
The importance of the SNS in the pathogenesis of hypertension has been defined in a variety of 341 
experimental models. Models of obesity-related hypertension demonstrate that increased renal 342 
sympathetic nerve activity and its attendant sodium avidity are key factors in the maintenance of 343 
sustained hypertension44 Rats that received daily infusions of phenylephrine for 8 weeks developed 344 
hypertension during the infusions; their BP normalized under a low salt diet after discontinuation of 345 
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phenylephrine, but once re-challenged with a high salt diet, the animals became hypertensive again37. 346 
The degree of BP elevation on the high salt diet was directly related to the degree of renal tubulo-347 
interstitial fibrosis and decrease in glomerular filtration rate, suggesting that catecholamine-induced 348 
hypertension causes renal interstitial injury and a salt-sensitive phenotype that persists even after 349 
sympathetic overactivity is no longer present. In addition, enhanced SNS activity results in alpha-1 350 
adrenergic receptor mediated endothelial dysfunction, vasoconstriction, vascular smooth muscle 351 
proliferation and increased arterial stiffness, which contribute to the development and maintenance of 352 
hypertension. Finally, there is evidence that sympathetic overactivity enhances salt-sensitivity due to a 353 
reduction in the activity of the With-no lysine kinase 4 (WNK4) gene, resulting in increased sodium 354 
avidity through the thiazide-sensitive Na-Cl co-transporter50. These mechanisms have been reviewed 355 
recently51. 356 
[H2] Inflammation and The Immune System 357 
 Inflammation, the biologic response to invading organisms, irritants or injury, makes an 358 
important contribution to the genesis of hypertension and target organ damage. Inflammation is 359 
associated with increased vascular permeability and release of potent mediators, such as reactive 360 
oxygen species, NO, cytokines, and metalloproteinases. Cytokines mediate neo-intima formation, thus 361 
decreasing the lumen diameter of resistance vessels, and promote vascular fibrosis, leading to 362 
increased vascular resistance and stiffness. Cytokines affect renal tubular function by increasing renal 363 
angiotensinogen production and tissue angiotensin II and promote sodium and volume retention in 364 
hypertension.iv Matrix metalloproteinases stimulate the degradation of the extracellular matrix, allowing 365 
infiltration of immune cells through the vessel wall into the interstitium of the affected organs, and 366 
activate other enzymes, promote apoptosis and enhance collagen synthesis and matrix deposition, 367 
leading to target organ damage. 368 
 While animal data are clear about the relationship between inflammation and hypertension, the 369 
data in humans are limited. There are associations between C-reactive protein, TNF-alpha and various 370 
interleukins and hypertension, but no direct link.  GWAS have identified a single nucleotide 371 
polymorphism of SH2B3 at position 262 (R262W) of LNK (SNP rs3184504) associated with many 372 
autoimmune and cardiovascular disorders, including hypertension.v Further, drugs that are used to treat 373 
inflammation, such as non-steroidal anti-inflammatory drugs and cyclosporine, raise rather than lower 374 
BP in hypertensive individuals, highlighting the complex nature of the relationship between 375 
inflammation and hypertension. 376 
 377 
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The immune system and the inflammatory response intensify the dysfunction of the kidney, 378 
vasculature and central nervous system as outlined above and promote hypertension and target-organ 379 
damage seen in hypertensive individuals, particularly if the inflammatory response is persistent or 380 
excessive.  Both innate and adaptive immune responses participate in the generation of reactive 381 
oxygen species and inflammatory changes in the kidneys, blood vessels and brain in hypertension52,53. 382 
Innate immune responses, especially those mediated by macrophages, have been linked to 383 
hypertension induced by angiotensin II, aldosterone and NO antagonism. Reductions in macrophage 384 
infiltration of the kidney or the peri-adventitial space of the aorta and medium sized arteries lead to 385 
reductions in BP and salt-sensitivity52. Adaptive immune responses via T cells have also been linked to 386 
the genesis of hypertension and its target organ damage. T cells express AT1 receptors and mediate 387 
angiotensin II-dependent hypertension,53 and it has been shown that depletion of mature lymphocytes 388 
ameliorated hypertension and kidney injury resulting from a high-salt diet in the Dahl SS rat54. Thus, a 389 
balance between proinflammatory T cell reactivity and inflammatory suppression induced by T 390 
regulatory cells determines the development of hypertension, as demonstrated by the amelioration of 391 
hypertension with the adoptive transfer of T regulatory cells in several animal models of hypertension52-392 
53. Abnormalities in both pro-inflammatory T cells and regulatory T cells are implicated in hypertension-393 
induced target organ damage, as they regulate the inflammatory processes in the kidney and 394 
vasculature that underlie hypertension-induced kidney disease52,53,54.  395 
 396 
[H1] DIAGNOSIS, SCREENING AND PREVENTION  397 
[H2] Diagnosis and screening 398 
Essential or primary hypertension is usually asymptomatic, thus the description of a silent killer and the 399 
recommendation to screen all subjects over 45 years of age has been suggested by many public health 400 
guidelines. Hypertension is most commonly diagnosed based on repeated BP measurements in an 401 
office setting. Accurate measurement and recording of BP is essential to categorize the level of BP, 402 
ascertain BP-related CVD risk and guide management. In the last decade, methods to measure out-of-403 
office BP have been increasingly introduced to guide diagnosis and treatment of hypertension55 56. 404 
These include home BP monitoring (HBPM) and ambulatory BP monitoring (ABPM). HBPM refers to 405 
the regular measurement of BP by an individual at their home or elsewhere outside the clinic setting. 406 
ABPM supplements BP readings in office settings, typically for the 24-hour period and while individuals 407 
go about their daily activities. Table 1 illustrates definitions of hypertension by office and out-of-office 408 
BP levels. The ability to measure out-of-office BP has allowed us to identify distinct BP phenotypes, 409 
including white coat or isolated clinic hypertension and masked or isolated ambulatory 410 
hypertension57,58. White coat hypertension is characterised by elevated office BP but normal readings 411 
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when measured using either ABPM or HBPM. In contrast, masked hypertension is characterised by 412 
normal office readings but out –of-office readings ( ABPM and HBPM ) are consistently above 413 
normal57,58.  414 
The evaluation of a patient with hypertension requires more that the diagnosis of high BP. It should also 415 
include assessment of the CV risk, target organ damage and any concomitant clinical conditions as well 416 
as recognition of features suggestive of secondary hypertension. Some of these investigations are 417 
necessary in all patients, but others only in specific patient groups. The medical history has to address 418 
the time of the first diagnosis of hypertension, current and past BP measurements and any 419 
antihypertensive medication. A history of pregnancy-related hypertension in women is an important 420 
factor. Hypertension translates into an increased risk of CV complications such as coronary heart 421 
disease, heart failure, atrial fibrillation, stroke and peripheral arterial disease, as well as chronic kidney 422 
disease. Therefore, a careful medical history should be taken in all patients to allow for assessment of 423 
global CV risk with a special emphasis on the current and past smoking habit and evidence of 424 
dyslipidaemia and diabetes. CVD risk should be estimated using an established calculator (e.g. 425 
http://ASCVD-Risk-Estimator/). Adults at high risk for CVD are the most likely to benefit from treatment 426 
and usually benefit from antihypertensive drug therapy in addition to lifestyle change61. 427 
A positive family history is a frequent feature in hypertensive patients, with the heritability estimated to 428 
vary between 35% and 50% in the majority of studies1,2. Several rare, monogenic forms of hypertension 429 
have been described, e.g., the Liddle’s syndrome or glucocorticoid-remediable aldosteronism, where a 430 
single gene mutation fully explains the pathogenesis of hypertension and dictates the best treatment 431 
modality3,4. However, the great majority of patients suffer from a highly heterogeneous “essential” or 432 
primary hypertension with a multifactorial gene-environment aetiology. Several GWAS have identified a 433 
large number of loci which are associated with BP regulation and together explain 3.5% of the trait 434 
variance6,7,8, 29. These findings are becoming increasingly important as we search for new pathways 435 
and new biomarkers to develop more modern “omics” driven diagnostic and therapeutic modalities for 436 
hypertension in the era of precision medicine9. Some of the most important environmental factors 437 
leading to high BP include overweight and obesity, excessive consumption of dietary sodium, 438 
insufficient intake of dietary potassium, physical inactivity and excessive intake of alcohol. 439 
The physical examination aims to establish the diagnosis of hypertension, screen for secondary causes 440 
and estimate the global CV risk (box 1). The patient should sit quietly for 5 minutes before a reading is 441 
taken and BP cuff should be at heart level. An average of 2 to 3 BP measurements obtained at 2 to 3 442 
separate occasions provide an accurate basis for estimation of BP59,60. At least once, BP should be 443 
measured on both arms, and differences in SBP > 20 mmHg and/or in DBP >10mmHg should initiate 444 
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investigations of vascular abnormalities59.Careful attention should be paid to choosing appropriately 445 
sized cuff, particularly for the increasing number of obese patients. Further, BP should be measured in 446 
both sitting and standing positions to rule out orthostatic hypotension. This is particularly important in 447 
older individuals. 448 
All patients should undergo auscultation of the carotid arteries, heart and renal arteries. Detection of 449 
murmurs should lead to further investigations: carotid ultrasound, echocardiography and renal 450 
ultrasound, respectively. An irregular pulse frequently indicates atrial fibrillation, which should be 451 
confirmed by an electrocardiogram (EKG). Laboratory investigations are used to detect additional risk 452 
factors, to confirm or exclude secondary hypertension and to detect clinical or sub-clinical target organ 453 
damage as illustrated in box 2. 454 
A small proportion of patients with hypertension have a potentially reversible cause of high BP, and a 455 
correct diagnosis might lead to a cure or a significant improvement in BP control with a reduction of CV 456 
risk. It is therefore appropriate to implement a simple screening for secondary hypertension in all 457 
patients. The screening is based on clinical history, physical examination and routine laboratory 458 
investigations (see above and Box 1 and 2). Secondary hypertension should also be considered in 459 
cases of a sudden worsening of hypertension, poor BP response to drug treatment and severe target 460 
organ damage, which is out of proportion to the duration and severity of hypertension. In these cases, 461 
specific diagnostic tests are indicated as described in Table 2.  462 
Despite overwhelming evidence that hypertension is a major treatable CV risk factor, studies across the 463 
world show that a large proportion of hypertensive subjects are either unaware of their high BP or 464 
aware but not treated or inadequately treated62,63. Thus, there is a strong indication to screen middle-465 
aged or younger persons in order to detect and treat more patients with hypertension. The most serious 466 
attempt by a healthcare system to improve the diagnostic aspects of hypertension has been done in the 467 
UK, based on pay-for-performance principle, i.e., to give incentives to general practitioners (primary 468 
care physicians) for the appropriate diagnosis and treatment of chronic diseases, including 469 
hypertension. An early report64,65 showed that this initiative was associated with an increased rate of BP 470 
monitoring and better BP control, but later reports suggested that this was not a sustained 471 
improvement66. It is possible that the recent initiative championed by the International Society of 472 
Hypertension and many national societies, which targeted entire populations by screening for 473 
hypertension in public places over the entire month of May 2017, might have better and more sustained 474 
results. 475 
 476 
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[H2] Prevention 477 
The association between hypertension and increased risk of CVD highlights the importance of 478 
treating hypertension, especially when severe. However, it also underscores the importance of 479 
strategies to reduce BP-related CVD risk in those who have a high normal level of BP. Reducing BP in 480 
adults with a high normal BP (referred to as elevated BP in the 2017 US guidelines) provides the 481 
potential to directly reduce CVD risk and to prevent or at least slow the age-related tendency for 482 
individuals to move into the much higher risk category of hypertension. 483 
In most countries there is a strong tendency for BP, especially systolic BP, and the prevalence 484 
of hypertension to increase progressively from childhood until late in life62. However, studies in isolated 485 
societies indicate that high BP is not an inevitable consequence of aging and that the rise in BP 486 
associated with local migration by members of isolated societies is related to changes in diet, 487 
decreased physical activity and consumption of alcohol67,68,69. These reports underscore the logic of 488 
efforts to prevent high BP in settings where an age-related increase in BP is common. A variety of 489 
nonpharmacological interventions have been shown to be effective in lowering BP and preventing 490 
hypertension. The most effective interventions are weight loss70,71,72, reduced Na+ intake70,71,72,73, 491 
increased potassium intake74,75, increased physical activity76, reduced consumption of alcohol77,78 and 492 
diets like the Dietary Approaches to Stop Hypertension (DASH) diet79 that combine several elements 493 
which favorably affect BP80,81 . The DASH diet is especially successful when combined with other 494 
effective BP lowering interventions such as a reduced intake of dietary sodium73. Lifestyle change is the 495 
best way for the individual to implement these interventions. Government agency and professional 496 
society websites provide helpful tips for lifestyle change and monitoring of BP. Even small 497 
improvements in an individual’s lifestyle can be valuable. Careful monitoring of BP is essential because 498 
the beneficial effects of lifestyle change are predicated on maintenance of the intervention82.  499 
Low-dose pharmacological therapy has also been shown to be effective in lowering BP and 500 
preventing hypertension in three randomized controlled trials conducted in adults with high normal 501 
BP83,84,85. The most recent of these, the Brazilian multi-center PREVER-Prevention Trial, compared 502 
treatment with the low-dose long-acting thiazide-like diuretic chlorthalidone (12.5 mg/day), in 503 
combination with the potassium sparing agent amiloride (2.5 mg/day) to treatment with placebo85. 504 
Treatment with the low-dose chlorthalidone/amiloride combination resulted in both a decrement in BP 505 
and prevention of hypertension and a reduction in left ventricular mass. A drug intervention is easier to 506 
implement and maintain than a lifestyle change intervention but there is a natural reluctance to 507 
recommend a lifetime of pharmaceutical therapy for prevention of hypertension. Consideration of low-508 
dose pharmacotherapy should be restricted to those who are at high risk of developing hypertension 509 
despite energetic efforts to lower BP by means of one or more nonpharmacological interventions.  510 
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Two complementary strategies aimed at achieving a small population-wide reduction in BP or a 511 
larger reduction in those who are at higher risk to develop hypertension can be employed to implement 512 
hypertension prevention interventions80,81,86. Modeling studies suggest that a downward shift of as little 513 
as 2 mmHg in the population distribution of diastolic BP would result in a 17% reduction in the 514 
incidence of hypertension, a 14% reduction in the risk of stroke and transient ischemic attacks, and a 515 
6% reduction in the risk of coronary heart disease87. Public health interventions focused on dietary 516 
improvements and increases in physical activity that are known to lower BP provide the basis for the 517 
population-wide strategy. Diet in the general population can be favorably influenced by means of public 518 
health education campaigns, food product labeling, and collaborations with food manufacturers to 519 
reduce the calorie and sodium content of their products, as well as with fast food companies and 520 
restaurants to reduce portion size and to promote healthier food preparation and promotion practices. 521 
Physical activity can be enhanced by making it easier for members of the community to engage in 522 
exercise on a routine basis. 523 
 524 
[H1] MANAGEMENT  525 
[H2] Treatment goals  526 
Following the publication of the Systolic blood PRessure Intervention Trial (SPRINT)88, target 527 
systolic BP values have been frequently debated. Before publication of SPRINT, most guidelines 528 
recommended a target BP < 140/90 mmHg for most hypertensive patients and < 150/90 mmHg for 529 
elderly patients over 60 or 80 years (Table 3)59,89. SPRINT was a randomized, open-label controlled trial 530 
that enrolled 9361 participants without diabetes but with increased CVD risk. Patients with a history of 531 
stroke were excluded. Participants were randomized to a standard systolic BP target < 140 mmHg or 532 
intensive systolic BP target < 120 mmHg. Intensive BP treatment in SPRINT resulted in a significantly 533 
greater (25%) reduction in the primary endpoint (first occurrence of myocardial infarction, acute 534 
coronary syndrome, stroke, heart failure, or death from cardiovascular causes), compared to standard 535 
treatment. Office BP measurement in SPRINT was performed with an automated device timed to start 536 
measurement after 5 minutes of rest in an effort to standardize measurements in the various clinics and 537 
minimize the white coat effect. Some observers have found large differences between automated office 538 
BP measurement and conventional auscultatory measurements (with the former technique showing 539 
lower values)90 and have on that basis questioned the applicability of the SPRINT intensive systolic BP 540 
target of < 120 mmHg to ordinary office practice91.  541 
Both the appropriate method(s) of measuring office BP (automated versus manual; unattended 542 
versus attended) and the appropriate BP targets for antihypertensive treatment are currently topics of 543 
vigorous debate. The 2016 Canadian Hypertension Education Program Guidelines recommend 544 
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intensive BP treatment with a target SBP ≤ 120 mmHg for selected high-risk patients based on 545 
automated office BP measurements92. The 2016 Australian guidelines recommend a target SBP < 120 546 
mmHg for selected high CV risk patients (without diabetes, including CKD patients and those >75 547 
years)( Table 3)93. The recently released US 548 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, 549 
Detection, Evaluation and Management of High Blood Pressure in Adults93a reassessed the issue of 550 
appropriate BP targets to recommend values < 130/80 mmHg for most patients. Individual goals based 551 
on clinical judgement and patient preference are suggested for older adults (≥ 65 years of age) with 552 
comorbidities and limited life expectancy. The 2013 ASH/ISH guidelines written to provide information 553 
for practitioners in low- and middle-income countries as well as in developed countries are more 554 
conservative, suggesting a goal of < 130/80 mmHg only for young adults and < 140/90 mmHg for the 555 
majority of hypertensive patients aged  55–80 years59a. Current ESH/ESC guidelines recommend a BP 556 
target of < 140/90 mmHg for the general population of adults with hypertension and a variety of 557 
comorbidities59 but a new version is expected in 2018. The recent American Diabetes Association 558 
(ADA) guidelines recommend a target of < 140/90 mmHg for the general population of adults with 559 
diabetes and a lower target (< 130/80 mmHg) for adults with diabetes who are at high risk for CVD and 560 
stroke94. In summary, newer guidelines published after the SPRINT trial seem to have more aggressive 561 
goals, at least for individuals < 65 years of age.  562 
 563 
[H2] Treatment thresholds 564 
Patient’s global CV risk and comorbidities should be considered in determining the need for 565 
pharmacologic antihypertensive treatment. This approach is used by the recent US 566 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, 567 
Detection, Evaluation and Management of High Blood Pressure in Adults93a. Use of antihypertensive 568 
medication is recommended in patients with pre-existing CVD and those without an event but an 569 
estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher at BP levels ≥ 570 
130/80 mmHg. In individuals without CVD and with 10-year ASCVD risk < 10%, antihypertensive 571 
medication should be initiated at BP ≥ 140/90 mmHg. For details, see Figure to be reproduced from 572 
reference 93a – Fig 4 page 73-74 (new Figure 5). 573 
 574 
[H2] Non-Pharmacological Management of Hypertension 575 
Lifestyle advice is recommended in all patients with hypertension. The most effective 576 
interventions are the same as for prevention of hypertension. Targeted dietary approaches can 577 
contribute to reduce the systolic BP in hypertensive individuals. Reducing sodium intake (ideally to 578 
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<2,300 mg/d, or <1,500 mg/d in those most susceptible to the effects of sodium on BP, but reduction by 579 
at least 1,000 mg/d is desirable) can lower the systolic BP by 2-4 mmHg, and a similar reduction can be 580 
expected with a potassium intake of 3,500 – 5,000 mg/d. Keeping alcohol intake ≤2 standard drinks/d 581 
for men and ≤1 standard drink/d for women can also contribute to a 2-4 mmHg BP reduction.  582 
[H3] Reduced salt intake 583 
Randomized controlled trials carried out in hypertensive persons have consistently shown that 584 
reduced sodium intake is associated with reduction of BP95. The most convincing evidence is provided 585 
by the Dietary Approaches to Stop Hypertension (DASH-sodium) trial73, in which the effects of three 586 
different sodium intakes were tested separately in combination with two diets: the DASH diet, rich in 587 
fruit, vegetables, low-fat dairy products and reduced in saturated fat and cholesterol, and the ‘usual 588 
American diet’. Reduction of sodium intake by approx. 0.9 g/day (40 mmol/day) induced a greater BP 589 
reduction when the starting sodium intake was <100 mmol/day. Of note, sodium reduction reduced BP 590 
in non-hypertensive individuals on both diets. DASH also provides evidence that increased potassium 591 
intake is associated with BP reduction. Reduced sodium intake can also prevent hypertension (relative 592 
risk reduction of about 20% with or without concomitant weight loss)72, improve hypertension control96 593 
and thus, possibly, reduce need for antihypertensive medication82. In the Intersalt study97, lower sodium 594 
intake was associated with a blunted age-related rise in systolic BP. 595 
The current recommendations of the American Heart Association98 and American Society of 596 
Hypertension99 are stricter than the European guidelines, recommending lowering intake to 3.8 g/day 597 
salt, whereas the 2013 ESH/ESC guidelines recommend 5–6 g of salt per day59. There is strong 598 
evidence to support population-wide recommendations to lower salt intake100,101 . As more than 75% of 599 
dietary salt comes from processed foods, any population strategy to reduce salt intake must involve 600 
food manufacturers and restaurants, in order to progressively reduce salt added to foods. So far, only 3 601 
countries (Japan, Finland, and the UK) have successfully reduced population salt intake102. 602 
[H3] Increased potassium intake 603 
High potassium intake is associated with reduced BP in individuals with low as well as high 604 
baseline potassium intake74. The effect of potassium on BP is dependent on salt intake. There is a 605 
greater BP reduction with increased potassium intake in the context of lower salt intake. Therefore, the 606 
best strategy is to increase potassium intake and reduce sodium intake at the same time. Potassium 607 
reduces BP to a greater extent in blacks than in whites103. The preferred strategy to increase potassium 608 
intake is to increase consumption of fruits and vegetables that are rich in potassium rather than using 609 
supplements99. In individuals with impaired urinary potassium excretion, a potassium intake < 4.7 g/d 610 
(120 mmol/d) is recommended. 611 
[H3] Moderate alcohol consumption 612 
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Keeping alcohol intake ≤2 standard drinks/d for men and ≤1 standard drink/d for women 613 
can also contribute to a 2-4 mmHg BP reduction. 77 614 
 615 
[H3] Physical activity 616 
Regular physical activity reduces BP in hypertensive individuals. A recent narrative review of 27 617 
randomized clinical trials in hypertensives showed that regular medium- to high-intensity aerobic activity 618 
reduced BP by a mean of 11/5 mmHg104. Sessions lasting 40-60 minutes performed at least three times 619 
a week had the greatest effect on BP. Three randomized controlled trials of isometric exercise showed 620 
a BP reduction of similar magnitude in hypertensives104. A meta-analysis of 64 controlled studies of the 621 
efficacy of dynamic resistance training as stand-alone antihypertensive therapy showed BP reductions 622 
comparable with or greater than those with aerobic exercise training. Greater BP reductions occurred in 623 
individuals with higher resting BP (approx. 6/5 mmHg for hypertension and 3/3 mmHg for pre-624 
hypertension) and in non-white individuals105. 625 
 626 
[H3] The Role of Weight Loss  627 
 Excess adiposity generally raises BP in susceptible individuals, and obese hypertensive 628 
patients require more antihypertensive medications to control their BP and are more likely to be 629 
treatment resistant106. Modest reductions in body weight lower systolic BP by on average 2-4 mmHg, 630 
however, the response varies substantially between individuals. Lifestyle interventions, including 631 
hypocaloric diets and physical exercise, are commonly recommended for patients with obesity and 632 
hypertension, yet average weight loss is modest and most patients regain weight107. Medications have 633 
been developed for the treatment of obesity, but their approval status differs between the U.S. and 634 
Europe: some drugs are only approved in the U.S. (e.g., lorcaserin and topiramate/phentermine), while 635 
others are approved in Europe only. BP reductions in patients with hypertension have been reported for 636 
some weight loss medications108, but drug-specific actions may attenuate the positive influences of 637 
weight loss on BP and CVD outcomes109. Bariatric surgery is very effective in reducing body weight, 638 
and the risk for arterial hypertension is substantially reduced up to five years following bariatric 639 
surgery110. However, large and sustained body weight reductions are needed to significantly reduce BP 640 
following bariatric surgery111 and there are no large clinical trials specifically testing the effects of weight 641 
loss medications or bariatric surgery on hypertension control.  642 
[H2] Antihypertensive Pharmacotherapy  643 
Antihypertensive pharmacotherapy has evolved over several decades driven by development of 644 
various antihypertensive medication classes and large-scale outcomes trials proving their benefits on 645 
CV morbidity and mortality112. Clinicians are now faced with a plethora of antihypertensive medications 646 
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of different drug classes and a variety of fixed dose combinations. Typically, antihypertensive 647 
pharmacotherapy is begun with first line antihypertensive medications either in monotherapy or in 648 
combination113. Combination therapy may be preferable in patients with higher levels of pretreatment 649 
BP. First line antihypertensive medications include angiotensin-converting enzyme inhibitors, 650 
angiotensin II receptor blockers (“sartans”), dihydropyridine calcium channel blockers, and thiazide 651 
diuretics89. Beta-blockers are also indicated in patients with heart failure and reduced left ventricular 652 
ejection fraction or post MI, and some guidelines recommend beta-blockers as first line 653 
antihypertensive medications 59,114. The choice should be based on individual efficacyand tolerability. 654 
Ethnicity affects the response to antihypertensive medications, and it has been suggested that calcium 655 
channel blockers and diuretics may be the first choice in blacks109,115. Further, in specific clinical 656 
situations, e.g. hypertension in pregnant women, other medications are preferable, while some first line 657 
antihypertensives, e.g. angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are 658 
contraindicated because of increased risk for renal teratogenicity. Divided dosing of antihypertensive 659 
drugs tends to decrease adherence and should be avoided when possible116.  660 
BP cannot be controlled with monotherapy in many patients, particularly those with severe 661 
hypertension. When combining antihypertensive medications, it is important to consider whether the 662 
drugs have additive effects on BP or side effects, and whether the patient has comorbidities that 663 
mandate particular drug choices59. Angiotensin-converting enzyme inhibitors or angiotensin receptor 664 
blockers, thiazide diuretics and dihydropyridine calcium channel blockers are additive in lowering BP 665 
and can be combined as double or triple combination therapies. In contrast, combining angiotensin-666 
converting enzyme inhibitors and angiotensin receptor blockers adds little BP lowering while increasing 667 
the risk for hyperkalemia and renal dysfunction. Similarly, combining RAAS inhibitors with beta-668 
adrenoreceptor blockers adds little BP reduction. This combination is indicated in patients following 669 
acute myocardial infarction or heart failure with reduced left ventricular ejection fraction for reasons 670 
beyond BP reduction 671 
 672 
[H3] Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. 673 
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have been tested 674 
extensively in large-scale hypertension trials117. In patients with heart failure with reduced left 675 
ventricular ejection fraction or with with diabetic nephropathy, both drug classes improved outcomes, 676 
making them particularly good choices in these populations. Both classes appear to be comparable in 677 
reducing CVD risk118. and also tend to improve glucose metabolism and thus may be preferable in 678 
younger patients and in patients with conditions predisposing to type 2 diabetes, including obesity and 679 
the metabolic syndrome119. Angiotensin-converting enzyme inhibitors are generally well tolerated, but 680 
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reductions in kidney function, hyperkalemia, cough, and – less commonly – angioedema may occur 681 
with their use. The risk for angioedema, which can be life threatening, is substantially increased in 682 
blacks120 and modestly increased in dipeptidyl peptidase-IV inhibitor (an antidiabetic drug) treated 683 
patients121. Angiotensin-converting enzyme inhibitors that can be dosed once daily are preferred. 684 
Angiotensin receptor blockers may also elicit hyperkalemia and worsening of kidney function, but are 685 
not likely to cause cough or angioedema118.  686 
 687 
[H3] Dihydropyridine calcium channel blockers. 688 
Dihydropyridine calcium channel blockers, which lower BP by blocking vascular L-type calcium 689 
channels, are effective antihypertensive drugs with extensive experience in large clinical trials117. A 690 
practical advantage of this drug class is that it can be combined with all other first-line 691 
antihypertensives. Peripheral edema, which is explained by peripheral arterial vasodilation rather than 692 
worsening heart failure or kidney dysfunction, is a common side effect, particularly in obese individuals. 693 
Non-dihydropyridine calcium channel blockers, especially verapamil, can induce or worsen 694 
constipation, especially in institutionalized older persons. Calcium channel blockers modestly inhibit the 695 
drug metabolizing enzyme cytochrome P450 3A4, and thus may elicit important drug-interactions122.  696 
 697 
[H3] Thiazide and thiazide-like diuretics. 698 
The thiazide/thiazide-type diuretics (hydrochlorothiazide and chlorothiazide) have a 699 
benzothiadiazine ring, while the thiazide-like diuretics (chlorthalidone, metolazone and 700 
indapamide) lack the benzothiadiazine structure. Both subclasses of diuretics inhibit Na+ and 701 
chloride co-transporters in renal tubules and have been an important component of 702 
pharmacological hypertension management ever since the first trials showing morbidity benefits 703 
of antihypertensive therapy123. Over the years, diuretic doses have been substantially reduced 704 
to attain better risk-benefit profiles. Thiazide diuretics may worsen glucose metabolism, but 705 
whether or not this metabolic action translates into long-term increases in CVD risk is unclear. 706 
Hydrochlorothiazide, the most commonly prescribed thiazide diuretic worldwide, may be less 707 
effective in mitigating CVD risk compared to chlorthalidone or indapamide124,125. Drug-related 708 
electrolyte disturbances, including hypokalemia and hyponatremia, are particularly important 709 
adverse effects. The risk for hypokalemia is reduced when thiazide diuretics are combined with 710 
potassium-sparing agents, such as angiotensin-converting enzyme inhibitors, angiotensin 711 
receptor blockers, or potassium-sparing diuretics. Hyponatremia is a potentially life threatening 712 
side effect, particularly in elderly persons.  713 
 714 
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[H3] Beta-adrenoreceptor blockers. 715 
Beta-adrenoreceptor blockers are thought to lower BP by inhibiting beta-adrenergic 716 
transmission in the kidney and the heart. They improve outcomes following acute myocardial infarction 717 
and in patients with heart failure with reduced left ventricular ejection fraction, but, in the absence of 718 
these comorbidities, beta-adrenoreceptor blockers appear to be inferior to other first line 719 
antihypertensives in reducing CVD morbidity and mortality126. This effect has been attributed to lesser 720 
reductions in central BP127 and adverse effects on body weight128 and glucose metabolism with beta-721 
adrenoreceptor blockade. Some of these disadvantages may be mitigated with newer vasodilator beta-722 
adrenoreceptor blockers, such as nebivolol and carvedilol129. However, there is no evidence from large-723 
scale antihypertensive trials that this difference translates into better clinical outcomes. Beta-724 
adrenoreceptor blockers may promote bronchial obstruction is patients with asthma and should not be 725 
combined with non-dihydropyridine calcium channel blockers such as verapamil that lower sinus node 726 
rate or atrioventricular conduction.  727 
 728 
 [H3] Newer Pharmacological Agents  729 
Overall, the interest of pharmaceutical industry in developing new antihypertensive medications 730 
has been limited in recent years. Some of the currently approved drugs, such as angiotensin receptor 731 
blockers, have placebo-like tolerability. Moreover, most antihypertensive drugs are out of patent and, 732 
therefore, available as relatively inexpensive generics. Novel pharmacological approaches approved for 733 
other indications, including combined angiotensin receptor and neprilysin inhibitors130, soluble guanylyl 734 
cyclase modulating drugs131, and sodium-glucose cotransporter 2 (SGLT2) inhibitors132 may be useful 735 
in treating hypertension. Other pharmacological approaches, such as novel mineralocorticoid receptor 736 
antagonists, aldosterone synthase inhibitors, activators of the angiotensin-converting enzyme 2/ 737 
angiotensin (1–7)/ MAS receptor axis, and natriuretic peptide receptor agonists, are in various stages of 738 
preclinical or clinical development133, often for indications other than hypertension. Drugs addressing 739 
novel mechanisms could be useful in patients with treatment resistant hypertension, particularly those 740 
not responding to or not tolerating mineralocorticoid receptor antagonists. Moreover, drugs with actions 741 
in addition to BP reduction could prove clinically useful. For example, combined angiotensin receptor 742 
blockade and neprilysin inhibition has been shown to ameliorate insulin resistance in obese 743 
hypertensive patients134 and decrease the progression to type 2 diabetes mellitus in heart failure 744 
patients135.  745 
 746 
[H2] Treatment Resistant Hypertension 747 
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Treatment resistant hypertension is commonly diagnosed when office BP is >140/90 mmHg 748 
despite treatment with three or more properly dosed antihypertensive drugs including a diuretic. 749 
Secondary causes of the hypertension have to be ruled out in order to make the diagnosis136. Poor 750 
treatment adherence is a common cause of apparent treatment resistant hypertension. The true 751 
prevalence of treatment resistant hypertension is unknown, but an estimated 12.8% of all individuals 752 
with hypertension in the United States and 15.3 % of those treated with antihypertensives fulfill the 753 
criteria for treatment resistant hypertension137. Adding a fourth or a fifth drug may lead to satisfactory 754 
BP control in these patients. The PATHWAY trial rotated patients with resistant hypertension through 755 
different add on drugs or placebo in a randomized fashion138. All patients received a standardized 756 
antihypertensive regimen comprising three drugs, including a diuretic. Compared with alpha- or beta-757 
adrenoreceptor blockade, the mineralocorticoid receptor antagonist spironolactone was the most 758 
effective fourth antihypertensive drug. In another study in patients uncontrolled on three drugs, 759 
sequential addition of a mineralocorticoid receptor antagonist followed by a loop diuretic was more 760 
effective than adding an ACE inhibitor followed by a beta-adrenoreceptor blocker139. Overall, 761 
mineralocorticoid antagonism is a reasonable choice in patients with difficult to control hypertension. 762 
Given the risk of inducing hyperkalemia140, serum potassium concentrations should be monitored.  763 
 764 
[H3] Device-based Treatments  765 
Device-based treatments have been primarily developed for patients with severe resistant 766 
hypertension whose BP cannot be controlled with antihypertensive drugs133. Catheter-based renal 767 
nerve ablation141,142, electrical carotid sinus stimulation143,144, modulation of baroreflex transduction with 768 
a dedicated carotid stent145, carotid body denervation146, and deep brain stimulation147 are thought to 769 
lower BP through SNS inhibition. Creation of a defined arteriovenous stent with a coupler device lowers 770 
BP by reducing peripheral vascular resistance148. These treatments are in various stages of clinical 771 
development, with the most extensive data available on renal nerve ablation and electrical carotid sinus 772 
stimulation. None has yet been proven efficacious in lowering BP in randomized sham-controlled 773 
clinical trials, and trials with hard clinical endpoints do not exist.  774 
  775 
 776 
[H1] QUALITY OF LIFE 777 
Health-related quality of life (HRQoL) is a multi-dimensional concept that includes domains 778 
related to physical, mental, emotional, and social functioning. Measurement of HRQoL is based on 779 
patient-self-report, yet has been extensively validated by studies demonstrating that each additional 780 
disease, as well as the severity of these diseases, is associated with declines in function149. Population-781 
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based studies have consistently shown that being diagnosed with hypertension is associated with 782 
worsening of HRQoL even after adjusting for other comorbidities150,151. Altered HRQoL in persons with 783 
hypertension has been attributed to a variety of factors, including the diagnosis, treatment, and effects 784 
of alterations (both elevations and reductions) in BP. 785 
The process of labeling someone as having hypertension can result in worsening of self-786 
perceived health status152. This was well-demonstrated in a classic study of otherwise healthy 787 
Canadian steelworkers identified as having hypertension as part of a screening program. In the year 788 
following diagnosis, absenteeism from work due to illness more than tripled in those made newly aware 789 
of their hypertension, while it increased only slightly in those previously aware of their hypertension153. 790 
This finding could not be explained by hypertension treatment or BP level and was believed to be a 791 
direct consequence of people adopting a “sick role.” These findings have been replicated in studies 792 
from diverse settings and using different measures of physical and mental health152. 793 
Antihypertensive medication use is associated with a variety of symptoms that could lower 794 
HRQoL154. In observational studies, being on more antihypertensive medications is associated with 795 
worse HRQoL155. Some classes of antihypertensive medications, e.g. angiotensin-converting enzyme 796 
inhibitors, are better tolerated than others, e.g. beta blockers and centrally acting agents, and result in 797 
significantly better scores on measures of general well-being156. Further, small differences in HRQoL 798 
have even been reported among medications of the same class, e.g., enalapril vs. captopril157. 799 
However, clinical trials with newer antihypertensive agents have generally indicated that they are 800 
extremely well-tolerated and can enhance the effects of non-pharmacologic treatment on HRQoL. In 801 
the Treatment of Mild Hypertension Study (TOMHS), combining lifestyle modifications with any of five 802 
different antihypertensive medication classes resulted in greater improvements in HRQoL than lifestyle 803 
modifications plus placebo158. 804 
Treatment-related reductions in BP may have a negative effect on HRQoL, particularly in older 805 
and more frail patients at high risk of hypotension. Older clinical trials evaluating patients with very high 806 
baseline BP, e.g., the Systolic Hypertension in the Elderly Program Trial (SHEP) and the Systolic 807 
Hypertension in Europe Trial (Syst-Eur), generally found minimal impact of BP reductions on 808 
HRQoL159,160. Two more recent clinical trials have targeted lower BPs (intensive systolic BP target < 809 
120 mmHg versus standard systolic BP target < 140 mmHg ), and it had been postulated that this lower 810 
BP might be expected to cause cerebral hypoperfusion, resulting in falls, dizziness, and cognitive 811 
impairment161,162,163. In a substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 812 
study, HRQoL was evaluated in 1,028 participants randomized to either intensive or standard therapy. 813 
No differences in mental function were noted between treatment groups, but intensive therapy was 814 
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associated with a small, not clinically significant, decrease in physical function162. In the Systolic Blood 815 
Pressure Intervention Trial (SPRINT), targeting systolic BP <120 mmHg required 1 additional 816 
antihypertensive medication compared to standard treatment to target systolic BP < 140 mmHg and 817 
was generally safe and well tolerated164. Compared to standard treatment, intensive treatment did not 818 
affect the perceived heath status of SPRINT participants, measured by patient reported outcomes of 819 
physical and mental health, self-reported satisfaction with care and medication adherence, even when 820 
stratifying on age and comorbidities164 . Almost 90% of participants in both treatment groups reported 821 
satisfaction with their BP care, and more than 1/3 described improvement in satisfaction over baseline 822 
levels.  823 
Quality of life concerns remain an important aspect of hypertension management. SPRINT has 824 
demonstrated that with careful clinical management, lower BP can be targeted without concern of 825 
worsening physical and mental function. Clinicians must seek the optimal balance of reducing CV 826 
morbidity and mortality while maximizing well-being for each individual patient.  827 
  828 
[H1] OUTLOOK 829 
The outlook for hypertension over the next 5 to 10 years is very variable, depending on where 830 
around the world you look. It is clear overall that the prevalence of hypertension and therefore the 831 
associated global burden attributable to hypertension, will increase165. This increase – 1.5 billion people 832 
are expected to be affected by 2025 (Ref. 166) – is largely due to global population growth and aging 833 
and will be focused in low and middle income countries165. However, these adverse trends in disease 834 
burden will be variably offset by improvements in prevention, awareness and treatment. The size of 835 
improvements in each of these 3 areas will vary from non-existent (in the case of prevention, a 836 
worsening in some parts of the world) to significantly large and important elsewhere.  837 
Overall, it is likely that prevention will contribute least to any improvement in BP-associated 838 
disease burden. That is because 80% of the world is in the process of “developing”, which hitherto has 839 
inevitably been associated with increased exposure to the main environmental determinants of raised 840 
BP such as excess intake of calories, alcohol and salt. To reverse this pattern requires the “buy-in” of 841 
the food and drink industries, governments, and education systems.  842 
Whilst moves in the right direction have taken place in relation to some of these preventive 843 
strategies, they have largely been limited to high income countries. It is also worrisome that despite 844 
reasonably compelling evidence to the contrary167, recommendations that the general population should 845 
restrict salt intake have been questioned on the basis of largely suboptimal observational data168. Such 846 
confusion worsens an already very difficult public health challenge. A lack of awareness of raised BP 847 
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status provides a great opportunity for reducing BP-associated health burden since recent data show 848 
that only approximately half of people with hypertension are aware of their condition169. Both the World 849 
Heart Foundation in their Roadmap for reducing CV mortality via lowering raised BP170, and the Lancet 850 
Commission on hypertension171 identified improved awareness of hypertension as a critical action 851 
needed to improve the current disease burden due to raised BP. It is hoped that the global BP 852 
awareness campaign instigated by the International Society of Hypertension whereby World 853 
Hypertension Day was extended to become May Measurement Month (MMM) in 2017 will contribute 854 
significantly to improving rates of routine BP screening around the world172. Over 1.25 million adults 855 
(≥18 years) from >100 countries were screened as part of MMM and it is hoped that the ensuing data 856 
allied to health-economic analyses will be used to persuade policy makers in each country that it makes 857 
clear financial sense to enhance local BP screening and treatment facilities.  858 
Improving the efficacy of drug treatment also holds great promise for reducing BP-associated 859 
disease burden. However, - rather than focusing on rare secondary causes of hypertension or the 860 
optimal management of “resistant hypertension”142 the biggest impact is likely to be achieved by the 861 
delivery and distribution of cheap, effective single-pill combinations of 2 or 3 drugs to low and middle 862 
income countries where most hypertension exists and where any such therapies are currently either 863 
largely unavailable or unaffordable173. 864 
Optimal combinations of 2 antihypertensive agents have not been identified for the majority of 865 
the world’s hypertensive population: no such data are available for black, south Asian or east Asian 866 
patients174. The first in a series of trials in these ethnic groups is underway in Sub-Saharan Africa. 867 
Meanwhile, single-pill combinations of the 3 drugs most commonly recommended in current guidelines 868 
(calcium channel blocker plus a diuretic, or calcium channel blocker plus a RAAS-blocker or diuretic 869 
plus a RAAS-blocker) are readily available and can be made very cheaply. In addition, a 3-drug 870 
combination of a calcium channel blocker, a diuretic and a RAAS-blocker114 should also be produced 871 
for more severe hypertension, with low dose spironolactone available as a fourth-line agent138. Hence, 872 
1 or 2 tablets will be able to control BPs of all but a small proportion of hypertensive patients.  873 
Means of making these formulations available cheaply to all countries of the world should be 874 
sought170. Distribution and delivery of these agents to hypertensive patients within each country also 875 
requires further circumnavigation of local obstacles170 – among which, the lack of an effective screening 876 
programme is critical. 877 
Those responsible for prescribing antihypertensive medications are likely to differ around the 878 
world. However, even in the higher income countries it is possible and certainly feasible that much of 879 
the “routine” uncomplicated hypertension management can, and probably should be carried out by 880 
nurse practitioners or other non-physician health workers.  In more remote parts of the world, the use of 881 
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e-healthcare techniques175 should be increasingly used to facilitate task-shifting or task sharing by non-882 
physician health-workers where doctors are unavailable176. 883 
In summary, whilst there are many outstanding and interesting scientific research questions in 884 
the field of hypertension (Box 3), perhaps the most urgently needed and important research required to 885 
reduce the BP-associated health burden is that which will evaluate the best way(s), at a local level, to 886 
screen routinely for raised BP and then to deliver the best, cheap, evidence-based combination of 887 
agents to those in need. Meanwhile, efforts to drive public health policy towards encouraging more 888 
healthy diets and lifestyle from a BP and CV viewpoint should be encouraged. More basic scientific 889 
research which might allow precision medicine to be applied to hypertension must also continue, whilst 890 
recognizing the larger and more pressing needs of implementing what is already known.  891 
 892 
 893 
   894 
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Box 1 – Physical examination for secondary hypertension, organ damage and obesity  895 
Signs suggestive of secondary hypertension 
 Features of Cushing’s syndrome 
 Neurofibromatosis (pheochromocytoma) 
 Enlarged kidneys (polycystic kidney) 
 Abdominal murmurs (renovascular hypertension) 
 Precordial murmurs (aortic coarctation, aortic disease) 
Signs of target organ damage 
 Brain - motor or sensory deficit 
 Retina - hypertensive retinopathy 
 Heart  - atrial fibrillation/arrhythmias 
- pulmonary congestion 
- peripheral oedema 
 Peripheral arteries - pulses absent, reduced or asymmetrical 
- Ischaemic skin lesions 
 Carotid arteries – murmurs 
Evidence of obesity 
 Weight and height 
 Calculate BMI: body weight/height2 
 Waist circumference 
 896 
897 
 Page 31 of 53 
 
Box 2 – Laboratory investigations  898 
 
Routine tests  
 Haemoglobin and haematocrit 
 Fasting plasma glucose 
 Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol 
 Fasting serum triglycerides 
 Serum potassium and sodium 
 Serum uric acid 
 Serum creatinine 
 Estimated glomerular filtration rate (eGFR) 
 Urine analysis including a test for microalbuminuria 
 12-lead EKG 
 
 
Additional tests based on history, clinical examination and routine tests 
 Haemoglobin A1c 
 Quantitative proteinuria 
 Out-of-office BP measurements* 
 Echocardiogram 
 Holter monitoring 
 Carotid ultrasound 
 Abdominal ultrasound 
 Pulse wave velocity 
 Ankle-brachial index 
 Further specialist tests for secondary hypertension (renin, aldosterone, 
catecholamines and their metabolites etc) 
 
 899 
*Ambulatory BP monitoring (ABPM) is recommended as the preferred method for measurement 900 
of “out-of-office” BPs to confirm high BP and to diagnose masked hypertension. Careful measurement 901 
of home BPs is acceptable when ABPM is not feasible. 902 
903 
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Box 3 Outstanding Research Questions:  904 
1. Measurement Issues: 905 
 Is hypertension management improved by basing treatment strategies on serial unattended 906 
BP measurements or, out of office (home or ambulatory) or central BP measurements? 907 
 How should BP be measured in patients with atrial fibrillation? 908 
2. Treatment Issues: 909 
 Should salt restriction at the population level continue to be recommended at current 910 
targets? 911 
 How far should age, estimated CVD risk and concomitant conditions influence treatment 912 
thresholds? 913 
 Should white-coat hypertension be treated?  914 
 If management strategy is to be influenced by central or out of office BP levels, what 915 
treatment thresholds and targets should be used?  916 
 Should reducing 24-hour and longer-term BP variability be a consideration in the selection 917 
of drug treatment for optimal CV protection? 918 
 What combinations of antihypertensive agents give optimal CV protection, stratified by age 919 
and ethnicity? 920 
 What is the optimal BP treatment target stratified by age, CV risk and concomitant disease 921 
status? 922 
 What is the optimal management of hypertension, truly resistant to 4 agents including 923 
Spironolactone.? 924 
 If treatment thresholds are to be driven by estimated CV risk at what level should 925 
antihypertensive drug treatment be initiated and what other CV protective agents should be 926 
considered? 927 
 Is initiating drug therapy with 2 hypertensive agents more effective than initiating with 928 
monotherapy for optimal CV prevention? 929 
  930 
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Figure 1: Map of age-standardized mean systolic blood pressure   931 
Reproduced from Ref. 14 932 
 933 
Figure 2. Systolic blood pressure and coronary heart disease  934 
Relationship of systolic BP to subsequent risk of coronary heart disease mortality during an average 935 
follow-up of 11.6 years in 347,978 US men aged 35-57 years at baseline. A | rates of coronary heart 936 
disease mortality per 10,000 person-years, adjusted for age, race, serum cholesterol, cigarettes 937 
smoked per day, use of medication for diabetes, and income for nine categories of baseline systolic BP. 938 
B | distribution of the sample by category of systolic BP. C | Estimation of the percent of excess 939 
coronary heart disease deaths occurring in each category of systolic BP ≥110 mm Hg, using those with 940 
a systolic BP <100 mm Hg as the reference group. Adapted, with permission, from Ref.17.  941 
 942 
Figure 3. Schematic drawing of the modern Page mosaic theory of hypertension. BP: Blood 943 
pressure, RAAS: renin-angiotensin-aldosterone system. 944 
 945 
Figure 4 Effects of chronic high salt intake  946 
The hemodynamic effects of chronic high salt intake differed between salt sensitive (SS) and salt 947 
resistant (SR) volunteers. Despite similar increases in cardiac output (row 3) and cumulative sodium 948 
balance (row 4), SS but not SR patients manifest salt-induced increases in mean arterial pressure (row 949 
1). Adapted from reference 37. 950 
 951 
Figure 5 Pathways affected in monogenic hypertensive disease. 952 
Thick ascending limb of the loop of Henle (TAL), distal convoluted tubule (DCT), and the cortical 953 
collecting tubule (CCT) are indicated, along with the pathway of the renin-angiotensin system, the major 954 
regulator of renal salt reabsorption. Inherited diseases affecting these pathways are indicated, with 955 
hypertensive disorders in red and hypotensive disorders in blue. Abbreviations: AI, angiotensin I; ACE, 956 
angiotensin converting enzyme; AII, angiotensin II (AII); MR, mineralocorticoid receptor; GRA, 957 
glucocorticoid-remediable aldosteronism; PHA1, pseudohypoaldosteronism, type-1; AME, apparent 958 
mineralocorticoid excess; 11 bHSD2, 11b-hydroxysteroid dehydrogenase-2; DOC, deoxycorticosterone; 959 
PT, proximal tubule and WNK, Serine/threonine-protein kinase. Modified from Ref3 960 
 961 
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Table 1 - Current definitions of hypertension by office and out-of-office BP levels 963 
Category Systolic 
BP 
 (mmHg) 
 Diastolic BP 
 (mmHg) 
Office BP ≥ 140 and/or ≥ 90 
Ambulatory BP    
 Daytime (awake) ≥ 135 and/or ≥ 85 
 Night time (asleep) ≥ 120 and/or ≥ 70 
 24hr ≥ 130 and/or ≥ 80 
Home BP ≥ 135 and/or ≥ 85 
Modified from Ref59. 964 
965 
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Table 2 – Diagnostics of secondary hypertension 966 
Clinical indications and diagnostics of secondary hypertension  967 
 Clinical indications Diagnostics 
Common causes Clinical history 
Physical 
examination 
Laboratory 
investigations 
First-line 
test(s) 
Additional/confirmatory 
test(s) 
Renal parenchymal 
disease 
History of urinary 
tract infection or 
obstruction, 
haematuria, 
analgesic abuse; 
family history of 
polycystic kidney 
disease 
Abdominal 
masses (in case of 
polycystic kidney 
disease) 
Presence of 
protein, 
erythrocytes, or 
leucocytes in the 
urine, decreased 
GFR 
Renal 
ultrasound 
Detailed work-up for 
kidney disease 
Renal artery 
stenosis 
Fibromuscular 
dysplasia: early 
onset hypertension 
(especially in 
women). 
Atherosclerotic 
stenosis: 
hypertension of 
abrupt onset, 
worsening or 
increasingly difficult 
to treat; flash 
pulmonary oedema  
Abdominal bruit 
Difference of 
>1.5 cm in 
length between 
the two kidneys 
(renal 
ultrasound), 
rapid 
deterioration in 
renal function 
(spontaneous or 
in response to 
RAA blockers)  
Renal Duplex 
Doppler 
ultrasonography 
Magnetic resonance 
angiography, spiral 
computed tomography, 
intra-arterial digital 
subtraction angiography 
Primary 
aldosteronism  
Muscle weakness; 
family history of 
early onset 
hypertension and 
cerebrovascular 
events at age <40 
years 
Arrhythmias (in 
case of severe 
hypokalaemia) 
Hypokalaemia 
(spontaneous or 
diuretic-
induced); 
incidental 
discovery of 
adrenal masses 
Aldosterone–
renin ratio 
under 
standardized 
conditions 
(corrected 
hypokalaemia 
and withdrawal 
of drugs 
affecting RAA 
system) 
Confirmatory tests (oral 
sodium loading, saline 
infusion, fludrocortisone 
suppression, or captopril 
test); adrenal CT scan; 
adrenal vein sampling 
Uncommon 
causes 
     
Pheochromocytoma  
Paroxysmal 
hypertension or a 
crisis superimposed 
to sustained 
hypertension; 
headache, sweating, 
palpitations and 
pallor; positive family 
history of 
pheochromocytoma 
Skin stigmata of 
neurofibromatosis 
(café-au-lait spots, 
neurofibromas) 
Incidental 
discovery of 
adrenal (or in 
some cases, 
extra-adrenal) 
masses 
Measurement 
of urinary 
fractionated 
metanephrines 
or plasma-free 
metanephrines 
CT or MRI of the 
abdomen and pelvis; 123I-
labelled meta-
iodobenzyl-guanidine 
scanning; genetic 
screening for pathogenic 
mutations 
Cushing’s syndrome 
Rapid weight gain, 
polyuria, polydipsia, 
psychological 
disturbances 
Typical body 
habitus (central 
obesity, moon-
face, buffalo 
hump, red striae, 
hirsutism) 
Hyperglycaemia 
24-h urinary 
cortisol 
excretion 
Dexamethasone-
suppression tests 
CT, computed tomography; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; RAA, renin–
angiotensin–aldosterone 
 968 
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Modified from Ref59. 969 
970 
 Page 38 of 53 
 
 Table 3. Blood pressure targets recommended by various guidelines 971 
Guideline Population Goal BP 
(mmHg) 
2013 ESH/ESC59 Non frail adults < 
80 years 
< 140/90 
Adults > 80 years < 150/90 
Adults with 
diabetes 
< 140/85 
Adults with CKD 
without proteinuria 
< 140/90 
Adults with CKD 
with overt 
proteinuria 
< 130/90 
Adults with CHD < 140/90 
2013 ASH/ISH59a Adults 55–80 years < 140/90 
Young adults < 130/80 
Elderly > 80 years < 150/90 
2014 Hypertension guideline89 (formerly known as JNC 8) Adults < 60 years < 140/90 
Adults ≥ 60 years < 150/90 
Adults with 
diabetes 
< 140/90 
Adults with CKD < 140/90 
CHEP 201692 Adults < 80 years < 140/90 
Adults ≥ 80 years < 150 
High-risk adults ≥ 
50 years 
≤ 120 
2016 Australian guidelines93 Adults at high CV 
risk without 
diabetes, including 
CKD patients and 
those >75 years 
< 120 mmHg 
 Adults with 
diabetes in whom 
< 120 mmHg 
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prevention of 
stroke is priority 
ADA94 Adults with 
diabetes 
< 140/90 
 Adults with 
diabetes and high 
risk for CVD 
< 130/80 
2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA9
3a 
Adults with  known 
CVD or 10-year 
ACVD event risk ≥ 
10%  
< 130/80 
Adults  without 
additional markers 
of increased CVD 
risk  
< 130/80 
Older adults ≥ 65 
years of age, 
noninstitutionalized
, ambulatory   
< 130/80 
Older adults ≥ 65 
years of age, with 
comorbidities and 
limited life 
expectancy 
Individualize
d goal based 
on clinical 
judgement 
and patient 
preference  
BP, blood pressure; ESH, European Society of Hypertension; ESC, European Society of Cardiology; 972 
CKD; chronic kidney disease; CHD, coronary heart disease; CHEP, Canadian Hypertension Education 973 
Program; ADA, American Diabetes Association; CVD, cardiovascular disease. ACC, American College 974 
Cardiology; AHA, American Heart Association; AAPA, American Academy of Physician Assistants; ABC, ; 975 
ACPM, American College of Preventive Medicine; AGE; AGS, American Geriatric Society; APhA, American 976 
Public Health Association; ASH, American Society of Hypertension; ASPC, American Society of 977 
Preventive Cardiology; NMA, National Medical Association; PCNA, Preventive Cardiovascular Nurses 978 
Association.  979 
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